Cellular immunotherapy for high-grade glioma

Immunotherapy

Volumn 3, Issue 3, 2011, Pages 423-434

  Chow, Kevin Kh ^a   Gottschalk, Stephen ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

cell therapy; gene therapy; glioma; immunotherapy; NK cell; T cell

Indexed keywords

BEVACIZUMAB; CANCER VACCINE;

BLOOD BRAIN BARRIER; CANCER IMMUNOTHERAPY; CELL THERAPY; GLIOBLASTOMA; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

ANTIGENS, NEOPLASM; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 79952665097     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.110     Document Type: Review

References (153)

1. DeAngelis LM: Brain tumors. N. Engl. J. Med. 344(2), 114-123 (2001).
2. Buckner JC: Factors influencing survival in high-grade gliomas. Semin. Oncol. 30(6 Suppl. 19), 10-14 (2003). (Pubitemid 38199157)
3. Okada H, Kohanbash G, Zhu X et al.: Immunotherapeutic approaches for glioma. Crit. Rev. Immunol. 29(1), 1-42 (2009).
4. Johnson LA , Sampson JH: Immunotherapy approaches for malignant glioma from 2007 to 2009. Curr. Neurol. Neurosci. Rep. 10(4), 259-266 (2010).
5. Mitchell DA , Sampson JH: Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics 6(3), 527-538 (2009).
6. Young H, Kaplan A, Regelson W: Immunotherapy with autologous white cell infusions ('lymphocytes') in the treatment of recurrrent glioblastoma multiforme: a preliminary report. Cancer 40(3), 1037-1044 (1977). (Pubitemid 8219454)
7. Steinbok P, Thomas JP, Grossman L, Dolman CL: Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme. A Phase I (toxicity) study. J. Neurooncol. 2(2), 147-151 (1984). (Pubitemid 14050558)
8. Vaquero J, Martinez R, Ramiro J, Salazar FG, Barbolla L, Regidor C: Immunotherapy of glioblastoma with intratumoural administration of autologous lymphocytes and human lymphoblastoid interferon. A further clinical study. Acta Neurochir. (Wien.) 109(1-2), 42-45 (1991).
9. Vaquero J, Martinez R, Oya S et al.: Intratumoural injection of autologous lymphocytes plus human lymphoblastoid interferon for the treatment of glioblastoma. Acta Neurochir. (Wien.) 98(1-2), 35-41 (1989). (Pubitemid 19135772)
10. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA: Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial. Cancer Res. 46(4 Pt 2), 2101-2104 (1986). (Pubitemid 16117915)
11. Yoshida S, Tanaka R, Takai N, Ono K: Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res. 48(17), 5011-5016 (1988).
12. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J. Neurosurg. 70(2), 175-182 (1989). (Pubitemid 19051711)
13. Hayes RL, Koslow M, Hiesiger EM et al.: Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76(5), 840-852 (1995).
14. Dillman RO, Duma CM, Ellis RA et al.: Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J. Immunother. 32(9), 914-919 (2009).
15. Dillman RO, Duma CM, Schiltz PM et al.: Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J. Immunother. 27(5), 398-404 (2004). (Pubitemid 39121929)
16. Ishikawa E, Tsuboi K, Saijo K et al.: Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 24(3b), 1861-1871 (2004). (Pubitemid 38954600)
17. Ingram M, Buckwalter JG, Jacques DB et al.: Immunotherapy for recurrent malignant glioma: an interim report on survival. Neurol. Res. 12(4), 265-273 (1990).
18. Lillehei KO, Mitchell DH, Johnson SD, McCleary EL, Kruse CA: Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28(1), 16-23 (1991).
19. Jeffes EW, III, Beamer YB, Jacques S et al.: Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. J. Neurooncol. 15(2), 141-155 (1993). (Pubitemid 23136029)
20. Quattrocchi KB, Miller CH, Cush S et al.: Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J. Neurooncol. 45(2), 141-157 (1999). (Pubitemid 30197728)
21. Plautz GE, Miller DW, Barnett GH et al.: T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res. 6(6), 2209-2218 (2000). (Pubitemid 30399186)
22. Plautz GE, Barnett GH, Miller DW et al.: Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg. 89(1), 42-51 (1998). (Pubitemid 28285921)
23. Peres E, Wood GW, Poulik J et al.: High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics 39(3), 151-156 (2008).
24. Kitahara T, Watanabe O, Yamaura A et al.: Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J. Neurooncol. 4(4), 329-336 (1987). (Pubitemid 17037579)
25. Tsuboi K, Saijo K, Ishikawa E et al.: Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin. Cancer Res. 9(9), 3294-3302 (2003). (Pubitemid 37082723)
26. Wheeler CJ , Black KL: DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin. Investig. Drugs 18(4), 509-519 (2009).
27. Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S, De Vleeschouwer S: Dendritic cell therapy of high-grade gliomas. Brain Pathol. 19(4), 694-712 (2009).
28. Ljunggren HG , Malmberg KJ: Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7(5), 329-339 (2007).
29. Leen AM, Rooney CM, Foster AE: Improving T cell therapy for cancer. Ann. Rev. Immunol. 25, 243-265 (2007). (Pubitemid 46697909)
30. Blattman JN, Greenberg PD: Cancer immunotherapy: a treatment for the masses. Science 305(5681), 200-205 (2004). (Pubitemid 38886725)
31. Humphrey PA, Wong AJ, Vogelstein B et al.: Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl Acad. Sci. USA 87(11), 4207-4211 (1990).
32. Bullain SS, Sahin A, Szentirmai O et al.: Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J. Neurooncol. (2009).
33. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS: HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 64(14), 4980-4986 (2004). (Pubitemid 38924546)
34. Sahin U, Koslowski M, Tureci O et al.: Expression of cancer testis genes in human brain tumors. Clin. Cancer Res. 6(10), 3916-3922 (2000).
35. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM: Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin. Cancer Res. 5(2), 335-341 (1999). (Pubitemid 29085187)
36. Debinski W, Slagle B, Gibo DM, Powers SK, Gillespie GY: Expression of a restrictive receptor for interleukin 13 is associated with glial transformation. J. Neurooncol. 48(2), 103-111 (2000).
37. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC: Specific recognition and killing of glioblastoma multiforme by interleukin 13-zkine redirected cytolytic T cells. Cancer Res. 64(24), 9160-9166 (2004). (Pubitemid 39665531)
38. Zhang JG, Eguchi J, Kruse CA et al.: Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin. Cancer Res. 13(2 Pt 1), 566-575 (2007). (Pubitemid 46225363)
39. Zhang JG, Kruse CA, Driggers L et al.: Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J. Neurooncol. 88(1), 65-76 (2008).
40. Ahmed N, Salsman VS, Kew Y et al.: HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16(2), 474-485 (2010).
41. Fujita M, Zhu X, Sasaki K et al.: Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J. Immunol. 180(4), 2089-2098 (2008).
42. Liu G, Yu JS, Zeng G et al.: AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J. Immunother. 27(3), 220-226 (2004). (Pubitemid 39118086)
43. Ueda R, Yoshida K, Kawase T, Kawakami Y, Toda M: Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Int. J. Cancer 120(8), 1704-1711 (2007). (Pubitemid 46399357)
44. Ueda R, Yoshida K, Kawakami Y, Kawase T, Toda M: Expression of a transcriptional factor, SOX6, in human gliomas. Brain Tumor Pathol. 21(1), 35-38 (2004). (Pubitemid 38915181)
45. Jin M, Komohara Y, Shichijo S et al.: Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. Oncol. Rep. 19(5), 1277-1283 (2008).
46. Harada M, Ishihara Y, Itoh K, Yamanaka R: Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncol. Rep. 17(3), 629-636 (2007).
47. Friese MA, Platten M, Lutz SZ et al.: MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 63(24), 8996-9006 (2003). (Pubitemid 38064081)
48. Wu A, Wiesner S, Xiao J et al.: Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy. J. Neurooncol. 83(2), 121-131 (2007).
49. Castriconi R, Daga A, Dondero A et al.: NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 182(6), 3530-3539 (2009).
50. Tsuda N, Nonaka Y, Shichijo S et al.: UDP-Gal: bGlcNAc b1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour. Br. J. Cancer 87(9), 1006-1012 (2002). (Pubitemid 35305654)
51. Hatano M, Eguchi J, Tatsumi T et al.: EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia. 7(8), 717-722 (2005).
52. Okada H, Low KL, Kohanbash G, McDonald HA, Hamilton RL, Pollack IF: Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J. Neurooncol. 88(3), 245-250 (2008).
53. Cobbs CS, Harkins L, Samanta M et al.: Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62(12), 3347-3350 (2002). (Pubitemid 34651375)
54. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El Zein R: Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 116(1), 79-86 (2008).
55. Mitchell DA, Xie W, Schmittling R et al.: Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro. Oncol. 10(1), 10-18 (2008). (Pubitemid 351250896)
56. Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C: The detection of CMV pp65 and IE1 in glioblastoma multiforme. DOI: 10.1007/s11060-010-0383-6 J. Neurooncol. (2010) (Epub ahead of print).
57. Lampson LA: Brain tumor immunotherapy: an immunologist's perspective. J. Neurooncol. 64(1-2), 3-11 (2003). (Pubitemid 36992455)
58. Tambur AR: Transplantation immunology and the central nervous system. Neurol. Res. 26(3), 243-255 (2004). (Pubitemid 38647178)
59. Khan-Farooqi HR, Prins RM, Liau LM: Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies. Neurol. Res. 27(7), 692-702 (2005). (Pubitemid 41513078)
60. de Vries NA, Beijnen JH, Boogerd W, van Tellingen O: Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev. Neurother. 6(8), 1199-1209 (2006). (Pubitemid 44231977)
61. Wu A, Wei J, Kong LY et al.: Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro. Oncol. 12(11), 1113-1125 (2010).
62. Wei J, Barr J, Kong LY et al.: Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol. Cancer Ther. 9(1), 67-78 (2010).
63. Di Tomaso T, Mazzoleni S, Wang E et al.: Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 16(3), 800-813 (2010).
64. Wei J, Barr J, Kong LY et al.: Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer Res. 16(2), 461-473 (2010).
65. Brown CE, Starr R, Martinez C et al.: Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res. 69(23), 8886-8893 (2009).
66. Hussain SF, Kong LY, Jordan J et al.: A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 67(20), 9630-9636 (2007). (Pubitemid 47621208)
67. Albesiano E, Han JE, Lim M: Mechanisms of local immunoresistance in glioma. Neurosurg. Clin. N. Am. 21(1), 17-29 (2010).
68. Avril T, Saikali S, Vauleon E et al.: Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. J. Neuroimmunol. 225(1-2), 22-33 (2010).
69. Jia W, Jackson-Cook C, Graf MR: Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model. J. Neuroimmunol. 223(1-2), 20-30 (2010).
70. Han SJ, Kaur G, Yang I, Lim M: Biologic principles of immunotherapy for malignant gliomas. Neurosurg. Clin. N. Am. 21(1), 1-16 (2010).
71. Humphries W, Wei J, Sampson JH, Heimberger AB: The role of Tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg. Clin. N. Am. 21(1), 125-137 (2010).
72. Poppema S: Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology (Am. Soc. Hematol. Educ. Program), 231-238 (2005).
73. Alvaro T, Lejeune M, Escriva P et al.: Appraisal of immune response in lymphoproliferative syndromes: a systematic review. Crit. Rev. Oncol. Hematol. 70(2), 103-113 (2009).
74. Bollard CM, Gottschalk S, Leen AM et al.: Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 110(8), 2838-2845 (2007). (Pubitemid 350006936)
75. Ridley A, Cavanagh JB: Lymphocytic infiltration in gliomas: evidence of possible host resistance. Brain 94(1), 117-124 (1971).
76. Palma L, Di Lorenzo N, Guidetti B: Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J. Neurosurg. 49(6), 854-861 (1978). (Pubitemid 9062914)
77. Brooks WH, Markesbery WR, Gupta GD, Roszman TL: Relationship of lymphocyte invasion and survival of brain tumor patients. Ann. Neurol. 4(3), 219-224 (1978). (Pubitemid 8389815)
78. Safdari H, Hochberg FH, Richardson EP Jr: Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas. Surg. Neurol. 23(3), 221-226 (1985). (Pubitemid 15138393)
79. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155(6), 1823-1841 (1982). (Pubitemid 12074218)
80. Law TM, Motzer RJ, Mazumdar M et al.: Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76(5), 824-832 (1995).
81. Fujisaki H, Kakuda H, Shimasaki N et al.: Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 69(9), 4010-4017 (2009).
82. Milone MC, Fish JD, Carpenito C et al.: Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17(8), 1453-1464 (2009).
83. Imai C, Mihara K, Andreansky M et al.: Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18(4), 676-684 (2004). (Pubitemid 38500185)
84. Diermayr S, Himmelreich H, Durovic B et al.: NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111(3), 1428-1436 (2008). (Pubitemid 351213430)
85. Ruggeri L, Mancusi A, Burchielli E et al.: NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol. Dis. 40(1), 84-90 (2008). (Pubitemid 350192306)
86. Ruggeri L, Capanni M, Urbani E et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562), 2097-2100 (2002). (Pubitemid 34229476)
87. Miller JS, Cooley S, Parham P et al.: Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109(11), 5058-5061 (2007). (Pubitemid 46827806)
88. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO: Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol. Immunother. 45(2), 77-87 (1997). (Pubitemid 27497682)
89. Bonneville M, O'Brien RL, Born WK: gd T cell effector functions: a blend of innate programming and acquired plasticity. Nat. Rev. Immunol. 10(7), 467-478 (2010).
90. Lamb LS, Jr: gd T cells as immune effectors against high-grade gliomas. Immunol. Res. 45(1), 85-95 (2009).
91. Yamaguchi T, Fujimiya Y, Suzuki Y, Katakura R, Ebina T: A simple method for the propagation and purification of g d T cells from the peripheral blood of glioblastoma patients using solid-phase anti-CD3 antibody and soluble IL-2. J. Immunol. Methods 205(1), 19-28 (1997). (Pubitemid 27297830)
92. Yamaguchi T, Suzuki Y, Katakura R, Ebina T, Yokoyama J, Fujimiya Y: Interleukin-15 effectively potentiates the in vitro tumor-specific activity and proliferation of peripheral blood gdT cells isolated from glioblastoma patients. Cancer Immunol. Immunother. 47(2), 97-103 (1998). (Pubitemid 28443560)
93. Fujimiya Y, Suzuki Y, Katakura R et al.: In vitro interleukin 12 activation of peripheral blood CD3+CD56+ and CD3+CD56- gd T cells from glioblastoma patients. Clin. Cancer Res. 3(4), 633-643 (1997).
94. Bryant NL, Suarez-Cuervo C, Gillespie GY et al.: Characterization and immunotherapeutic potential of gd T-cells in patients with glioblastoma. Neuro. Oncol. 11(4), 357-367 (2009).
95. Bryant NL, Gillespie GY, Lopez RD et al.: Preclinical evaluation of ex vivo expanded/ activated gd T cells for immunotherapy of glioblastoma multiforme. J. Neurooncol. 101(2), 179-188 (2010).
96. Wilhelm M, Kunzmann V, Eckstein S et al.: gd T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1), 200-206 (2003). (Pubitemid 36759655)
97. Dieli F, Vermijlen D, Fulfaro F et al.: Targeting human gd T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67(15), 7450-7457 (2007). (Pubitemid 47206575)
98. Laport GG, Levine BL, Stadtmauer EA et al.: Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 102(6), 2004-2013 (2003). (Pubitemid 37122373)
99. Rapoport AP, Stadtmauer EA, Aqui N et al.: Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11(11), 1230-1237 (2005). (Pubitemid 43093671)
100. Rapoport AP, Stadtmauer EA, Aqui N et al.: Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin. Cancer Res. 15(13), 4499-4507 (2009).
101. Porter DL, Levine BL, Bunin N et al.: A Phase I trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 107(4), 1325-1331 (2006). (Pubitemid 43242365)
102. Rapoport AP, Aqui NA, Stadtmauer EA et al.: Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination based on hTERT and survivin following ASCT for myeloma. Blood 117(3), 788-797 (2011).
103. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8(4), 299-308 (2008). (Pubitemid 351430867)
104. Dudley ME, Wunderlich JR, Robbins PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002). (Pubitemid 35231542)
105. Dudley ME, Yang JC, Sherry R et al.: Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233-5239 (2008).
106. Balch CM, Riley LB, Bae YJ et al.: Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch. Surg. 125(2), 200-205 (1990). (Pubitemid 20060644)
107. Straathof KC, Bollard CM, Popat U et al.: Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105, 1898-1904 (2005). (Pubitemid 40731770)
108. Bollard CM, Aguilar L, Straathof KC et al.: Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's disease. J. Exp. Med. 200(12), 1623-1633 (2004). (Pubitemid 40094186)
109. Comoli P, Pedrazzoli P, Maccario R et al.: Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23(35), 8942-8949 (2005). (Pubitemid 46211479)
110. Leen AM, Myers GD, Sili U et al.: Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12(10), 1160-1166 (2006). (Pubitemid 44527351)
111. Peggs KS, Verfuerth S, Pizzey A et al.: Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 362(9393), 1375-1377 (2003). (Pubitemid 37338339)
112. Yee C, Thompson JA, Byrd D et al.: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99(25), 16168-16173 (2002). (Pubitemid 35462767)
113. Hunder NN, Wallen H, Cao J et al.: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358(25), 2698-2703 (2008). (Pubitemid 351860862)
114. Morgan RA, Dudley ME, Rosenberg SA: Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J. 16(4), 336-341 (2010).
115. Xue SA, Gao L, Thomas S et al.: Development of a WT1-TCR for clinical trials: engineered patient T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica 95(1), 126-134 (2009).
116. Stanislawski T, Voss RH, Lotz C et al.: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2(10), 962-970 (2001). (Pubitemid 32976170)
117. Engels B , Uckert W: Redirecting T lymphocyte specificity by T cell receptor gene transfer - a new era for immunotherapy. Mol. Aspects Med. 28(1), 115-142 (2007).
118. Johnson LA, Morgan RA, Dudley ME et al.: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3), 535-546 (2009).
119. Morgan RA, Dudley ME, Wunderlich JR et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006). (Pubitemid 44547756)
120. Eshhar Z, Waks T, Gross G, Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the g or z subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90(2), 720-724 (1993). (Pubitemid 23028937)
121. Pule M, Finney H, Lawson A: Artificial T-cell receptors. Cytotherapy 5(3), 211-226 (2003).
122. Sadelain M, Riviere I, Brentjens R: Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3(1), 35-45 (2003). (Pubitemid 37328885)
123. Pule MA, Savoldo B, Myers GD et al.: Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14(11), 1264-1270 (2008).
124. Till BG, Jensen MC, Wang J et al.: Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112(6), 2261-2271 (2008).
125. Jena B, Dotti G, Cooper LJ: Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116(7), 1035-1044 (2010).
126. Vera JF, Hoyos V, Savoldo B et al.: Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol. Ther. 17(5), 880-888 (2009).
127. Quintarelli C, Vera JF, Savoldo B et al.: Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 110(8), 2793-2802 (2007). (Pubitemid 350006931)
128. Kerkar SP, Muranski P, Kaiser A et al.: Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70(17), 6725-6734 (2010).
129. Stephan MT, Ponomarev V, Brentjens RJ et al.: T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13(12), 1440-1449 (2007). (Pubitemid 350224246)
130. Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA: Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J. Immunother. 33(7), 672-683 (2010).
131. Foster AE, Dotti G, Lu A et al.: Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-b receptor. J. Immunother. 31(5), 500-505 (2008).
132. Bollard CM, Rossig C, Calonge MJ et al.: Adapting a transforming growth factor b-related tumor protection strategy to enhance antitumor immunity. Blood 99(9), 3179-3187 (2002). (Pubitemid 34525296)
133. Dotti G, Savoldo B, Pule M et al.: Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 105(12), 4677-4684 (2005). (Pubitemid 40807289)
134. Gardner RA, Reik A, Berger C et al.: Disruption of glucocorticoid regulation in therapeutic human T cells with zinc finger nucleases. Mol. Ther. 18(Suppl. 1), S240 (2010).
135. Sawai N, Zhou S, Vanin EF, Houghton P, Brent TP, Sorrentino BP: Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol. Ther. 3(1), 78-87 (2001). (Pubitemid 32509808)
136. Yaghoubi SS, Jensen MC, Satyamurthy N et al.: Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat. Clin. Pract. Oncol. 6(1), 53-58 (2009).
137. Mitsuyasu RT, Anton PA, Deeks SG et al.: Prolonged survival and tissue trafficking following adoptive transfer of CD4z gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus-infected subjects. Blood 96(3), 785-793 (2000). (Pubitemid 30616838)
138. Walker RE, Bechtel CM, Natarajan V et al.: Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 96(2), 467-474 (2000). (Pubitemid 30463364)
139. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M: Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRz/CD28 receptor. Nat. Biotechnol. 20(1), 70-75 (2002). (Pubitemid 34044918)
140. Yvon E, Del Vecchio M, Savoldo B et al.: Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin. Cancer Res. 15(18), 5852-5860 (2009).
141. Landmeier S, Altvater B, Pscherer S et al.: Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. Cancer Res. 67(17), 8335-8343 (2007). (Pubitemid 47395172)
142. Savoldo B, Rooney CM, Di Stasi A et al.: Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30z artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 110(7), 2620-2630 (2007). (Pubitemid 47523186)
143. Cooper LJ, Al Kadhimi Z, Serrano LM et al.: Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 105(4), 1622-1631 (2005). (Pubitemid 40223683)
144. Ghazi A, Salsman VS, Kew Y et al.: CMV-specific HER2-Redirected T cells for the Adoptive Immunotherapy of Glioblatstoma. Mol. Ther. 18(Suppl. 1), S182 (2010).
145. Kershaw MH, Wang G, Westwood JA et al.: Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 13(16), 1971-1980 (2002). (Pubitemid 35341038)
146. Craddock JA, Lu A, Bear A et al.: Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33(8), 780-788 (2010).
147. Louis CU, Straathof K, Bollard CM et al.: Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 113(11), 2442-2450 (2009).
148. Park MY, Kim CH, Sohn HJ, Oh ST, Kim SG, Kim TG: The optimal interval for dendritic cell vaccination following adoptive T cell transfer is important for boosting potent anti-tumor immunity. Vaccine 25(42), 7322-7330 (2007).
149. Song XT, Turnis M, Zhou X et al.: A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol. Ther. 19(1), 211-217 (2010).
150. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA: Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70(15), 6171-6180 (2010).
151. Vo DD, Prins RM, Begley JL et al.: Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 69(22), 8693-8699 (2009).
152. Herrmann A, Kortylewski M, Kujawski M et al.: Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells. Cancer Res. 70(19), 7455-7464 (2010).
153. Bucy P: Commentary on: Primary brain tumors: tumor immunity and immunocompetence. Surg. Neurol. 1(5), 263 (1973).